| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T7 |
1-14 |
NN |
denotes |
glycosylation |
| T8 |
16-24 |
NN |
denotes |
Abstract |
| T9 |
25-31 |
JJ |
denotes |
Severe |
| T10 |
32-37 |
JJ |
denotes |
acute |
| T11 |
38-49 |
JJ |
denotes |
respiratory |
| T12 |
50-58 |
NN |
denotes |
syndrome |
| T13 |
59-60 |
-LRB- |
denotes |
( |
| T14 |
60-64 |
NN |
denotes |
SARS |
| T15 |
64-65 |
-RRB- |
denotes |
) |
| T16 |
66-69 |
CC |
denotes |
and |
| T17 |
70-76 |
NNP |
denotes |
Middle |
| T18 |
77-81 |
NNP |
denotes |
East |
| T19 |
82-93 |
JJ |
denotes |
respiratory |
| T20 |
94-102 |
NN |
denotes |
syndrome |
| T21 |
103-104 |
-LRB- |
denotes |
( |
| T22 |
104-108 |
NNS |
denotes |
MERS |
| T23 |
108-109 |
-RRB- |
denotes |
) |
| T24 |
110-123 |
NNS |
denotes |
coronaviruses |
| T25 |
124-125 |
-LRB- |
denotes |
( |
| T26 |
125-129 |
NNS |
denotes |
CoVs |
| T27 |
129-130 |
-RRB- |
denotes |
) |
| T28 |
131-134 |
VBP |
denotes |
are |
| T29 |
135-143 |
JJ |
denotes |
zoonotic |
| T30 |
144-153 |
NNS |
denotes |
pathogens |
| T31 |
154-158 |
IN |
denotes |
with |
| T32 |
159-163 |
JJ |
denotes |
high |
| T33 |
164-172 |
NN |
denotes |
fatality |
| T34 |
173-178 |
NNS |
denotes |
rates |
| T35 |
179-182 |
CC |
denotes |
and |
| T36 |
183-191 |
JJ |
denotes |
pandemic |
| T37 |
192-201 |
NN |
denotes |
potential |
| T38 |
203-210 |
NN |
denotes |
Vaccine |
| T39 |
211-222 |
NN |
denotes |
development |
| T40 |
223-230 |
VBZ |
denotes |
focuses |
| T41 |
231-233 |
IN |
denotes |
on |
| T42 |
234-237 |
DT |
denotes |
the |
| T43 |
238-247 |
JJ |
denotes |
principal |
| T44 |
248-254 |
NN |
denotes |
target |
| T45 |
255-257 |
IN |
denotes |
of |
| T46 |
258-261 |
DT |
denotes |
the |
| T47 |
262-274 |
VBG |
denotes |
neutralizing |
| R10 |
T12 |
T13 |
arg1Of |
syndrome,( |
| R11 |
T14 |
T13 |
arg2Of |
SARS,( |
| R12 |
T15 |
T13 |
arg3Of |
),( |
| R13 |
T12 |
T16 |
arg1Of |
syndrome,and |
| R14 |
T20 |
T16 |
arg2Of |
syndrome,and |
| R15 |
T18 |
T17 |
arg1Of |
East,Middle |
| R16 |
T20 |
T18 |
arg1Of |
syndrome,East |
| R17 |
T20 |
T19 |
arg1Of |
syndrome,respiratory |
| R18 |
T20 |
T21 |
arg1Of |
syndrome,( |
| R19 |
T22 |
T21 |
arg2Of |
MERS,( |
| R20 |
T23 |
T21 |
arg3Of |
),( |
| R21 |
T28 |
T24 |
arg1Of |
are,coronaviruses |
| R22 |
T24 |
T25 |
arg1Of |
coronaviruses,( |
| R23 |
T26 |
T25 |
arg2Of |
CoVs,( |
| R24 |
T27 |
T25 |
arg3Of |
),( |
| R25 |
T16 |
T28 |
arg1Of |
and,are |
| R26 |
T30 |
T28 |
arg2Of |
pathogens,are |
| R27 |
T30 |
T29 |
arg1Of |
pathogens,zoonotic |
| R28 |
T30 |
T31 |
arg1Of |
pathogens,with |
| R29 |
T35 |
T31 |
arg2Of |
and,with |
| R30 |
T34 |
T32 |
arg1Of |
rates,high |
| R31 |
T34 |
T33 |
arg1Of |
rates,fatality |
| R32 |
T34 |
T35 |
arg1Of |
rates,and |
| R33 |
T37 |
T35 |
arg2Of |
potential,and |
| R34 |
T37 |
T36 |
arg1Of |
potential,pandemic |
| R35 |
T39 |
T38 |
arg1Of |
development,Vaccine |
| R36 |
T39 |
T40 |
arg1Of |
development,focuses |
| R37 |
T40 |
T41 |
arg1Of |
focuses,on |
| R38 |
T44 |
T41 |
arg2Of |
target,on |
| R39 |
T44 |
T42 |
arg1Of |
target,the |
| R40 |
T44 |
T43 |
arg1Of |
target,principal |
| R41 |
T44 |
T45 |
arg1Of |
target,of |
| R7 |
T12 |
T9 |
arg1Of |
syndrome,Severe |
| R8 |
T12 |
T10 |
arg1Of |
syndrome,acute |
| R9 |
T12 |
T11 |
arg1Of |
syndrome,respiratory |
